EFTA00299761.pdf

BioReference L Aar, , ,,: ATC: 9 I ES PRELIMINARY C/PKO ORSHER, STUART EPSTEIN, JEFFREY Specimen I' 104659439 D08: 41/20/1953 Age:64 V skate i Date Of APport.,,f44414NOP-65:29 IIIII U/FL: Bed: Date Collected: 09/19/2017 08:57 C3070 - STUART ORSHER, M.D. • RM: Date Received: 09/15/2017 23:06 9 EAST 79TH ST, Patient 10: NEW YORK, NY 18021 Address:9 EAST 71ST STREET. INW YORK, HY 10021 Acct PO P. P: Ateth MiltriCO EOS tern rime Dotes: NON FASTING NOTE: SST tube submitted was inadequately spun. Serum was found to contain ReCs. Certain tests, e.g. Glucose, nay be decreased while ethers e.g. Potassium or LOH may be elevated. CLINICAL REPORT (Nay not contain all abnormal results: narrative results say not have abnormal Clinical Abnormalities Summary: flags. Please review entire report.) Cholesterol 224 HI Triglycerides 646 HI HDL CHOL., DIRECT 29 LO HEN as % of 13 • rhol/HOL Ratio 7.7 NON-HDL 115 HI Cholesterol CHOLESTEROL HEP. A Ab., TOTAL Reactive HEP. B SURF. A3. Reactive 250H, VITAMIN D 31.5 LO PTH(3), INTACT 106.0 HI Albumin 4.7 3.5.5.2 g/dL 4.5 08/30/2017 ---.. Calcium -- -.e/di. 1RVAW:felY"' CARDIOVASCULAR/LIPIDS "-- Cholesterol doe mg/dL 08/30/2017 iTriayearides <150 ragiar. S .471atHZ 0E/30/2017 : NOL CHOL., DIRECT >40 mg/dL TRIP 08/30/2017 MK •.• as• % of cholesterol 13 • >la 'INP • 08/3437Trir2 1 it Evaluation: MOVE AVO.(PODERATE RISK) :Chol/HDL Ratio 7.7 • <7.4 MP 1 08/3e/2917., Evaluation: ABOVE 4vG.(RODERATE RISK) , rlDIVA0L Aiii0 " - Can't Cili <3.50 iNON.HDL CHOLESTEROL 195 HZ <130 0.0L%Chelestendk • . can't calc <100 iiT&-- Cortri n ta - ::13:::71. . .. . . . • • i. ISSTEit:imable to calculate 101 dojos a Triglyceride lent of greater then 400agidt, • • • • .0.6C—CALCULATED Can't Calc 7-32 mg/dL f Can't adc TOSV2017 can't Calc: One or more components was outside the measurable range. We are unable to calculate. 794 1.770 0.178-4.530 u1U/aL 08/30/2017 THVROXINE(T4) 4.9.121 ustiE EN/30/3017 SioReference Laboratories, Inc. James Weisberger M.D. Page 1 of 4 481 Edward H. Ross OP I elmmoon Park. N/07487 I Laboratory Director printed 09/19/2017 11:48 EFTA00299761  PRELIMINARY BioRef erence ABORATORiES er OPKO Hecon Convene EPSTEIN, JEFFREY -----) Specimen ID: 104659439 ORSHER, STUART Date Of Report: 09/19/2917 05:29 DOB: 01/26/1953 Age: 64 V Six: M U/Fl: Bed: Date Collected: 09/15/2017 08:57 3078 - STUART ORSHER, M.D. Rm: Date Received: 09/15/2017 23:06 9 EAST 79TH ST, Patient ID: Address:, EAST Tut STREET, NEW YORK, NY 10021 NEW YORK, NY 10021 Acct #: (03870) MO P. 11: North America Eastern 7itte CLINICAL REPORT -- eve IM a bodies say occasionally pees ct for more than 12 --months post -infection. i --Test developed and characteristics determined by ARDS Laboratories. See Compliance Statement A: eruplab.com/Cs --www.aruplab.com, lull.° Delgado, MD - Lab. Director • B. quintana Ab, IgG <1:64 i --INTERPRETIVE MS092447104: Bartonella quintana Antibody, IgG Less than 1:64 Negative: No significant level of I .. Bartonella quintana XgG antibody detected. ; 1:64 - 1:123 Equivocal: Questionable presence of Bartonella quintana IgG antibody detected. Repeat tasting in 10-14 days may be helpful. :• 1466 or greater Positive: Presence of /6 -- antibody to Bartonella quintana detected, suggestive of current or past infection. . --A IOW:positive suggests past exposure or infection, while high --positive results may indicate recent or current infection, but is --inconclusive.for diagnosis. Seroconversion between acute and -=convalescent sera is considered strong evidence of recent ; -infection. The best evidence for infection is a significant change two appropriately timed specimens where both tests are done in --the same laboratory at the same time. --Test developed and characteristics determined by ARUP --Laboratories. See Coepliance Statement A: aruplab.com/CS Nip. dil. Noe: NOD-Riective . Reactive Ab. (S/C0 RATIO) 0.03 41.80 ! • PerforMed by: ARUP 500 Chipeta Nay Salt Lake City, UI 8.41013 Hepatitis B Result Interpretation (for reference use only) Marker Li/EA* Acute Past Chronic RSV See. issAg + + + NBeAe + + +/- NIP.B.,CORE A6,IgM + - tRIP.ECORE AB. + + + Warn: +/- +/- . +/- + *LateIntileation/Early Acute NOTE: In remote past infection, H9sAb level may be Negative or JarnesWeiabergorld.D. Page 3 of 4 BioReference laboratories, Inc. Laboratory Director Printed 09/19/2017 11:48 481 Edward H. Ross D- I Elmwood Park. N) 07407 EFTA00299762  BioReference : Al:ORATORI ES PRELIMINARY an OPKO HasIth Company ORSNER, STUART EPSTEIN, iEFFREY Specimen ID: 104659439 I DOB: 01/20/1953 Ago: 64 V Sex: M Date Of Report: 09/19/2017 05:29 C3070 - STUART ORSHER, M.D. /FL: Bed: Date Collected: 09/15/2017 08:57 Date Received: 09/15/2017 23:06 9 EAST 79TH ST. Patient xo: NEW YORK, NY 18021 Address:9 EAST 71ST STREET, NEW YORK, NY 20021 Ct 8: (C3070) P: North asertco foster,' nee CLINICAL REPORT FOLIC ACID 7.77 >5.38 .. Tap -101110/i617— Folic Acid Range Units (ng/mli Normal >5.38 Borderline deficient 3.38.5.38 Deficient 0.35-3.37 Excessive >24.00 359 . . .150K, IfITEX/N D 31.8 LO nth& _ . . : VITAMIN 0,25-00 TEST INFORMATION Range (ng/mL) Suggested Interpretation <20.0 Deficient 20.0-31.9 Insufficient 32.0-100.0 Sufficient >100.8 Possible Adverse Effects 'Mt "' 52.0 ' 19.9-7.4 pest 96/30/2017 INTACT 106.0 HI 13.8-85.0 pg/mL 08/34/2017 TO POLE <0.3 LO OBA7/5317 : ;Aiuko- nb T Oi b (58) TO FOLLOW 4.4 08/30/2017 ArTgi, — -16 -- Alkupt Ab tipe 8 (si) TO FOLLOW 0.4 Le 00/30/2017 PNEUMO AD TYPE 9 (9N) (58) TO FOLLOW 0.4 LO 08/30/2017 (*MSC 0 TYPE 12 (12P) (58) TO FOLLOW (0.3 LO 00/30/2017 ifsNEUMO Ab TYPE 14 (58) TO FOLLOW 23.2 08/30/2017 * OrimUMO-A*O-ttOkii*(IOW(51) * TO FOLLOW' - 8.8 LO eniSehr ro 41**(23)**(MO' POLLai 48;3 LO ea/se/atir: PNEUMO Ab TYPE 26 SO tss) to OoLLow 8.5 lo 08/30/2017 PNEUMO Ab TYPE 5'(58) TO FOLLOW 7.8 08/30/2817 PNEUMO Ab TYPE Si (7F) (58)." 000•61 is 06/30%2017 IFINEUND'Ab TYPE 56: (18C) (58) TO FOLLOW 1.3 LO 08/30/2017 ;ONEOMO ii*,*tyPE (58) TO 0.4 LO • 08/30/2017 t i4ense5i-Triirar Ab (3) TO FOLLOW ea/seneii •• . NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience. sloReference Laboratories, Inc. JnosembYelebergmrhILD. Page 4 of 4 481 Edward H. Ross Dr I Elmwood Park, NT 07407 I LaboratoryDirector Printed 09/19/2017 11:48 EFTA00299763 EFTA00299764